Literature DB >> 16757213

Medicines for Malaria Venture: sustaining antimalarial drug development.

Ian Bathurst1, Chris Hentschel.   

Abstract

The Medicines for Malaria Venture (MMV) is committed to discovering, developing and delivering new drugs for malaria. Founded in 1999 as a nonprofit organization bringing private sector management methods to bear on a global public health problem, MMV is today recognized as a leader among the public-private partnerships working on diseases for the developing world. Together with its many partners, MMV manages the world's largest malaria research and development portfolio, covering the innovation spectrum from basic drug discovery to late-stage development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757213     DOI: 10.1016/j.pt.2006.05.011

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  21 in total

Review 1.  Cooperative development of antimicrobials: looking back to look ahead.

Authors:  Carl Nathan
Journal:  Nat Rev Microbiol       Date:  2015-10       Impact factor: 60.633

Review 2.  Drug discovery for malaria: a very challenging and timely endeavor.

Authors:  Michael H Gelb
Journal:  Curr Opin Chem Biol       Date:  2007-08       Impact factor: 8.822

3.  In vivo antimalarial activity of Trichilia megalantha harms extracts and fractions in animal models.

Authors:  Dorcas A Fadare; Oyindamola O Abiodun; Edith O Ajaiyeoba
Journal:  Parasitol Res       Date:  2013-06-26       Impact factor: 2.289

4.  Natural product-inspired aryl isonitriles as a new class of antimalarial compounds against drug-resistant parasites.

Authors:  Kwaku Kyei-Baffour; Dexter C Davis; Zarko Boskovic; Nobutaka Kato; Mingji Dai
Journal:  Bioorg Med Chem       Date:  2020-08-01       Impact factor: 3.641

5.  In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.

Authors:  Eric H Ekland; David A Fidock
Journal:  Int J Parasitol       Date:  2008-04-01       Impact factor: 3.981

Review 6.  Malaria resurgence: a systematic review and assessment of its causes.

Authors:  Justin M Cohen; David L Smith; Chris Cotter; Abigail Ward; Gavin Yamey; Oliver J Sabot; Bruno Moonen
Journal:  Malar J       Date:  2012-04-24       Impact factor: 2.979

7.  Mining a cathepsin inhibitor library for new antiparasitic drug leads.

Authors:  Kenny K H Ang; Joseline Ratnam; Jiri Gut; Jennifer Legac; Elizabeth Hansell; Zachary B Mackey; Katarzyna M Skrzypczynska; Anjan Debnath; Juan C Engel; Philip J Rosenthal; James H McKerrow; Michelle R Arkin; Adam R Renslo
Journal:  PLoS Negl Trop Dis       Date:  2011-05-03

8.  Structural modifications of quinoline-based antimalarial agents: Recent developments.

Authors:  Sandhya Bawa; Suresh Kumar; Sushma Drabu; Rajiv Kumar
Journal:  J Pharm Bioallied Sci       Date:  2010-04

9.  A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.

Authors: 
Journal:  PLoS Med       Date:  2011-11-08       Impact factor: 11.069

10.  Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.

Authors:  Steffen Borrmann; Tim Peto; Robert W Snow; Win Gutteridge; Nicholas J White
Journal:  PLoS Med       Date:  2008-11-18       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.